Subject: To understand the diagnostic practices & treatment preference in the management of ovarian cancer
As per Globocan data, incidences of ovarian cancer are 48,014 in India. Ovarian cancer patients may have pre-existing co-morbidities or gene mutations.
Currently for the management of ovarian cancer, there different treatment regimens being used. The treatment choice can differ on the basis of co-morbid conditions or gene mutation status. For BRCA/HRD+ve patients, PARP inhibitors are available that improves PFS in such patients.
As there are multiple treatment choices available for the management of ovarian cancer, thorough understanding of current diagnostic testing practice & doctor’s choices in the management of ovarian cancer patients is crucial.
We invite you to participate in this survey and share relevant information about the management of platinum sensitive relapsed ovarian cancer in real world practice in India.
We trust you and we are partners in promoting safe effective medical therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})